Poolbeg Pharma Valuation
Is POLB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for POLB.F?
Other financial metrics that can be useful for relative valuation.
| What is POLB.F's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | UK£44.50m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -7.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does POLB.F's PB Ratio compare to its peers?
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
ODTC Odonate Therapeutics | 0.7x | n/a | US$52.7m |
SHWZ Medicine Man Technologies | 0.4x | n/a | US$61.6m |
HEPA Hepion Pharmaceuticals | 1x | -21.4% | US$55.6m |
CGTX Cognition Therapeutics | 1.2x | -23.4% | US$47.7m |
POLB.F Poolbeg Pharma | 2x | -3.3% | US$44.5m |
Price to Earnings Ratio vs Industry
How does POLB.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price to Book Ratio vs Fair Ratio
What is POLB.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate POLB.F's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of POLB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?